Catheter Precision Files 8-K with Corporate Updates

TL;DR

CATM filed an 8-K on 8/13/25 covering corporate changes, amendments, and financial docs.

AI Summary

On August 13, 2025, Catheter Precision, Inc. filed an 8-K report detailing several events. These include material modifications to the rights of security holders, amendments to its articles of incorporation or bylaws, and other events. The filing also includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate actions and potential changes affecting Catheter Precision, Inc.'s structure and security holders.

Risk Assessment

Risk Level: medium — The filing involves material modifications and amendments, which can introduce uncertainty or changes in security holder rights.

Key Players & Entities

• Catheter Precision, Inc. (company) — Registrant
• August 13, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-38677 (identifier) — Commission File Number
• 38-3661826 (identifier) — I.R.S. Employer Identification No.
• 1670 Highway 160 West – Suite 205, Fort Mill, SC 29708 (address) — Principal executive office address

FAQ

Key Financial Figures

• $0.0001 — ompany's issued common stock, par value $0.0001 per share (the "Common Stock"), at a ra

Filing Documents

• vtak20250813_8k.htm (8-K) — 33KB
• ex_852916.htm (EX-3.1) — 11KB
• 0001437749-25-027153.txt ( ) — 181KB
• vtak-20250813.xsd (EX-101.SCH) — 3KB
• vtak-20250813_def.xml (EX-101.DEF) — 12KB
• vtak-20250813_lab.xml (EX-101.LAB) — 15KB
• vtak-20250813_pre.xml (EX-101.PRE) — 12KB
• vtak20250813_8k_htm.xml (XML) — 3KB

03. Material Modification to Rights of Security Holders

Item 3.03. Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information in Item 5.03 of this report is incorporated herein by reference.

03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. As previously reported in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on July 28, 2025, Catheter Precision, Inc. ("we," "us," "our" or the "Company") held its 2025 annual meeting (the "Annual Meeting") of stockholders on July 25, 2025, at which the Company's stockholders approved the proposal to give the Company's board of directors (the "Board") the authority, at its discretion, to file a certificate of amendment to the Company's restated certificate of incorporation, as amended, to effect a reverse split of the Company's issued common stock, par value $0.0001 per share (the "Common Stock"), at a ratio not less than 1-for-5 and not greater than 1-for-19, with the exact ratio to be selected by the Board in its discretion and to be effected, if at all, in the sole discretion of the Board at any time following stockholder approval of the proposal and without further approval or authorization of the Company's stockholders. Subsequently, the Board determined to effect a reverse split of the Common Stock (the "Reverse Stock Split") at a ratio of 1-for-19 (the "Reverse Stock Split Ratio"). On August 13, 2025, the Company filed a certificate of amendment to the Company's restated certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect the Reverse Stock Split (the "Charter Amendment"). The Charter Amendment became effective at 12:01 a.m. Eastern Time on August 15, 2025, and the Common Stock began trading on a split-adjusted basis at the opening of trading on the NYSE American on August 15, 2025. The Common Stock will continue to trade under its existing symbol "VTAK," but the Common Stock has been assigned a new CUSIP number (74933X 708). Following the Reverse Stock Split, every 19 shares of Common Stock issued, including shares held by the Company in treasury, if any, was automatically recl

01 Other Events

Item 8.01 Other Events. The information in Item 5.03 of this report is incorporated herein by reference. The Company has registration statements on Form S-1 No. 333-262195, Post Effective Amendment to S-1 No. 333-240187, S-1 No. 333-239887, S-1 No. 333-237701, S-3 No. 333-267443, S-1 (Post Effective Amendment to S-3) No. 333-269491, S-3 No. 333-271388, S-1 (Post Effective Amendment to S-3) No. 333-270919, S-8 No. 333-264495, S-8 No. 333-254370, S-8 No. 333-250094, S-8 No. 333-237096, S-8 No. 333-230332, S-8 No. 333-227696, S-8 No. 333-269612, S-8 No. 333-273351, S-3 No. 333-284217, S-1 No. 333-283392, Post Effective Amendment to S-1 No. 333-281849, S-1 No. 333-279930, S-8 No. 333-280786, S-3 No. 333-287483, and S-8 No. 333-288348 on file with the SEC (collectively, the "Registration Statements"). SEC regulations permit the Company to incorporate by reference future filings made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the termination of the offerings covered by these registration statements. The information incorporated by reference is considered part of the prospectus included within each of those registration statements. Information in this Item 8.01 is intended to be automatically incorporated by reference into each of these Registration Statements, thereby amending them. Pursuant to Rule 416(b) under the Securities Act of 1933, as amended, the amount of undistributed shares of Common Stock deemed covered by the Registration Statements was proportionately reduced as of the effective time of the Reverse Stock Split at the Reverse Stock Split Ratio.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment of Restated Certificate of Incorporation dated August 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -3-

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CATHETER PRECISION, INC. Date: August 15, 2025 /s/ Philip Anderson Philip Anderson Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR